AB Science SA AB
EURONEXT · France · Health Technology
€0.5820-0.01 (-1.36%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the new management, given priority to the development of a new quality management system Expected resumption of the AB8939 phase 1 (acute myeloid leukemia) in the first quarter of 2027, followed by the masitinib phase 3 (amyotrophic lateral sclerosis) in the last quarter of 2027, subj
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL SETTLEMENT AND DELIVERY OF SECURITIES ISSUED AS PART OF ITS €14.2 MILLION PRIVATE PLACEMENT ANNOUNCED ON AUGUST 10, 2026 Paris, August 17, 2026, 7.30am CET AB Science S.A. (the “Company” or “AB Science,” Euronext – FR0010557264 – AB) today announces the successful settlement and delivery of the securities issued as part of its capital increases subscribed to by a limited number of investors and announced on August 10, 2026 (the “Private Placement
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.